IKT · Inhibikase Therapeutics, Inc.

The thesis

Inhibikase Therapeutics is a one-drug company whose shares have kept falling, and the third-quarter report due in mid-November settles whether the funding story still supports them. The shares closed at $1.62 on 28 October 2026, down from $1.83 on 15 October 2026 and 35.7% below the $2.52 52-week high (adjusted daily closes). That close is below the $1.80 level the previous note set as its invalidation level, and the three-month price change is -25.7%.

The drug, IKT-001, is an imatinib prodrug in the Phase 3 IMPROVE-PAH trial for pulmonary arterial hypertension (PAH). No result, guidance change or financing has been reported since the previous note. The two company items since 15 October 2026 are administrative: a board appointment on 20 October 2026 and a notice of November investor-conference participation on 27 October 2026.

The narrative is maturing and losing momentum: the story is well known, and the shares sit below the $2.00 price of the 14 July 2026 financing. Chardan Capital's $1.50 target (initiated at Neutral on 13 October 2026) is now close to the market price. The clinical readout is mid-2028 by management's projection, so the dated events in between are cash and enrollment updates.

Bullish and bearish views on Inhibikase Therapeutics, Inc.

The bull case on Inhibikase Therapeutics, Inc. (IKT), in brief: The trial is running globally. The bear case: The price keeps sliding.

Bull case

• The trial is running globally. The 8 September 2026 corporate presentation (Form 8-K exhibit) reported 46 active sites, up from 43 on 11 August 2026, with approvals in 26 countries.
• The 14 July 2026 sale of 25 million shares to RA Capital Management raised $50 million gross.
• The drug has regulatory support. The FDA granted Orphan Drug Designation to IKT-001 for PAH on 23 July 2026 (company announcement via Benzinga).
• Most analysts remain positive. MarketBeat's 28 September 2026 summary of nine brokerages showed four buy and three strong-buy ratings, one hold and one sell, with an average 12-month target of $5.40. These are the analysts' views, and that summary predates the 13 October 2026 Chardan initiation.

Bear case

• The price keeps sliding. The close fell from $2.00 on 2 October 2026 to $1.83 on 15 October 2026 and $1.62 on 28 October 2026. The 14-day relative strength index (RSI) read 33.5 on 28 October 2026, near the level that usually marks heavy selling.
• A cautious analyst target sits near the price. Chardan Capital initiated at Neutral on 13 October 2026 with a $1.50 target. The shares closed at $1.62 on 28 October 2026.
• The readout is far away. Management's 8 September 2026 presentation places Part A efficacy results (change in pulmonary vascular resistance at Week 24) in mid-2028 and interim safety results in the first half of 2027.
• Dilution is open-ended. The 11 August 2026 report counts 132.0 million common shares plus 42.5 million pre-funded warrants. The RA Capital at-the-market facility remains available, and the 14 July 2026 sale was priced at $2.00 per share, above the current price.
• Spending is rising. Research and development expense was $13.4 million in the quarter ended 30 June 2026, against $5.3 million a year earlier. Management's guidance to fund operations through Part B topline results depends on timely warrant exercise, which becomes harder to count on with the shares below $2.00.

Price setup

The adjusted close was $1.62 on 28 October 2026. The 52-week high is $2.52. On 28 September 2026 MarketBeat gave the 50-day moving average as $2.35 and the 200-day as $2.01, so the shares trade well under both.

The $1.80 level named in the previous note has been broken. The next reference points are Chardan's $1.50 target and the open question of how much further the shares fall before the quarterly report. An RSI of 33.5 shows persistent selling without yet reaching the sub-30 range.

Crowding evidence is limited to what can be observed. The earnings date is inside 30 days. The at-the-market facility is open, and RA Capital bought shares through it at $2.00. No SEC Form 4 insider filings were reported in the last 30 days.

Catalysts, next 30 days

• ~16 November 2026, est.: Third-quarter 2026 financial results and program update. The company reported Q3 2025 on 14 November 2025 and Q2 2026 on 11 August 2026. Benzinga lists a consensus loss of about $0.11 per share. A confirmed date has not been announced.
• 2027 first half (company projection): IMPROVE-PAH interim safety results, the first trial data in the program.

Elapsed catalysts

• November 2026, dates per company notice: Investor-conference participation, announced 27 October 2026. Management commentary on enrollment and funding may come out here. (passed 10d ago)

What would change the view

The case breaks if the third-quarter report withdraws or qualifies the expectation of funding through Part B topline results, if enrollment is suspended, or if site and country counts fail to rise past 46 and 26. New at-the-market sales at prices below $2.00 would add supply and widen dilution. A daily close below $1.50, Chardan's target, would extend the decline past the only published target near the market price.

Evidence for a better read would be rising site counts, spending in line with the $19.6 million second-quarter loss, and no new share sales in the report.

What it trades with

IKT trades on its own financing and trial news. A single asset with a readout in mid-2028 leaves little scheduled news between now and then. Small-cap biotech funds and the broader risk appetite for pre-revenue drug developers set the background, and no peer or index reading is cited here.